Effectiveness and medication adherence in patients with ST- elevated myocardial infarction: Persian polypill study
- PMID: 40103623
- PMCID: PMC11913457
- DOI: 10.48305/arya.2025.43212.3007
Effectiveness and medication adherence in patients with ST- elevated myocardial infarction: Persian polypill study
Abstract
Background: Polypill or fixed-dose combination has been recognized as an effective secondary prevention strategy for patients with cardiovascular disease (CVD). This study aimed to evaluate the effectiveness of the polypill on one-year medication adherence, patient satisfaction, and lipid profile control in patients with ST-elevation myocardial infarction (STEMI).
Methods: This was an open-label, multicentric, randomized clinical trial study of STEMI patients who were prescribed a polypill (Aspirin 81 mg, Atorvastatin 40 mg, Metoprolol Succinate 47.5 mg, and Valsartan 40 mg) versus usual care (continued with separate medications) for secondary prevention. The primary outcome was to compare one-year medication adherence between groups. Other outcomes included comparing patient satisfaction and lipid profile after 12 months of follow-up, as well as identifying predictor factors of medication adherence.
Results: Of 624 STEMI participants, 289 patients were treated with the polypill (79.2% male; mean age 61.67 ± 8.54 years), and 335 patients received usual care (82.7% male; mean age 62.10 ± 9.63 years). After one-year follow-up, no significant differences were detected between groups regarding medication adherence (p-value = 0.351) and cholesterol levels (p-value = 0.808). The polypill strategy was associated with increased patient satisfaction and better control of LDL-C (p-value = 0.043) and HDL-C (p-value < 0.001). Patients with a history of chronic kidney disease (OR: 13.392; p-value = 0.001), cerebrovascular disease (OR: 4.577; p-value = 0.011), and higher waist circumference (OR: 1.01; p-value = 0.002) demonstrated a lower probability of medication adherence. In contrast, in-hospital complications such as arrhythmia (OR: 0.039; p-value = 0.010), bleeding (OR: 0.034; p-value = 0.007), and higher ejection fraction (OR: 0.965; p-value = 0.002) were associated with a higher probability of medication adherence.
Conclusion: In STEMI patients, participants treated with polypills were more satisfied and showed better lipid profile control. However, a longer follow-up duration is needed to examine the effectiveness of the polypill on medication adherence in this subgroup.
Keywords: Lipids; Medication Adherence; Patient Satisfaction; Polypill; ST Elevation Myocardial Infarction.
Conflict of interest statement
All authors declare that there is no conflict of interest.
Similar articles
-
A polypill strategy to improve adherence: results from the FOCUS project.J Am Coll Cardiol. 2014 Nov 18-25;64(20):2071-82. doi: 10.1016/j.jacc.2014.08.021. Epub 2014 Sep 1. J Am Coll Cardiol. 2014. PMID: 25193393 Clinical Trial.
-
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.Eur J Prev Cardiol. 2015 Jul;22(7):920-30. doi: 10.1177/2047487314530382. Epub 2014 Mar 27. Eur J Prev Cardiol. 2015. PMID: 24676715 Clinical Trial.
-
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.Cerebrovasc Dis Extra. 2020;10(3):166-173. doi: 10.1159/000511064. Epub 2020 Nov 11. Cerebrovasc Dis Extra. 2020. PMID: 33176324 Free PMC article.
-
The Impact of Polypill on Adherence and Cardiovascular Outcomes: A Comprehensive Systematic Review with Meta-Analysis.Curr Cardiol Rev. 2024;20(2):61-71. doi: 10.2174/011573403X283174240110025442. Curr Cardiol Rev. 2024. PMID: 38265377 Free PMC article.
-
Effect of the Polypill on Adherence and Prevention of Cardiovascular Diseases in Patients With or at High Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.Cureus. 2023 Jan 24;15(1):e34134. doi: 10.7759/cureus.34134. eCollection 2023 Jan. Cureus. 2023. PMID: 36843692 Free PMC article. Review.
References
-
- Bhatt DL, Lopes RD, Harrington RA. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022 Feb 15;327(7):662–75. - PubMed
-
- Kingma J. Myocardial infarction: An overview of STEMI and NSTEMI physiopathology and treatment. World J Cardiovasc Dis. 2018;8(11):498–517.
-
- Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet. 2021;397(10279):1085–94. - PubMed
LinkOut - more resources
Full Text Sources